Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting
# Biodexa’s (NASDAQ:BDRX) Licensor Emtora’s Phase 2 Clinical Trial Results of FAP Treatment eRapa™ to Be Presented Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company with an emphasis on acquisitions, is eagerly announcing that Emtora Biosciences, its licensor, will present the results from their Phase 2 clinical trial on eRapa for the treatment of […]